CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
15 hedge funds and large institutions have $1.58M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
Holders
15
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$151K | |
| 2 | +$1.64K | |
| 3 | +$986 | |
| 4 |
CG
Colony Group
Boston,
Massachusetts
|
+$548 |
| 5 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$11 |
Top Sellers
| 1 | -$292K | |
| 2 | -$43.8K | |
| 3 | -$32.1K | |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$28.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.49K |